BNT162b2
Tozinameran is an RNA vaccine composed of nucleoside-modified mRNA encoding a mutated form of the spike protein of SARS-CoV-2. The vaccination requires two doses given three weeks apart. Pfizer has advanced purchase agreements of about USD 3 billion for providing a licensed vaccine in the United States, European Union, United Kingdom, Japan, Canada, and Peru.
About BNT162b2 in brief
Tozinameran is a COVID-19 vaccine developed by BioNTech and manufactured and distributed by Pfizer. It is an RNA vaccine composed of nucleoside-modified mRNA encoding a mutated form of the spike protein of SARS-CoV-2, and is encapsulated in lipid nanoparticles. The vaccination requires two doses given three weeks apart. The vaccine’s ability to prevent severe infection in children, pregnant women, or immune-compromised people, and its duration of immune effect are unknown. Pfizer has advanced purchase agreements of about USD 3 billion for providing a licensed vaccine in the United States, European Union, United Kingdom, Japan, Canada, and Peru. BNT162b2 is a continuous-phase trial in Phase III as November 2020, with the trial expanding to tens of thousands of people during mid-2020. The early-stage research on BNT 162b2 determined the safety and dose level for the vaccine. The trial is still ongoing, and monitoring the primary outcomes continues until August 2021, and the secondary outcomes to January 2023.
In October 2020, preliminary results from Phase I–II clinical trials showed better safety and efficacy of BNT161b2. In December 2020, the European Medicines Agency began a periodic review of the efficacy and safety of the vaccine candidate. In September 2020, Pfizer indicated in November that 50 million doses could be available globally by the end of 2020, and about 1. 3 billion doses by mid-2021. In March 2020, German company BioNTtech received a USD 135 million investment from Fosun in exchange for 1. 58 million shares in BioNTTech and the future development and marketing rights of B NT162b 2 in China. Pfizer CEO Albert Bourla stated that he decided against taking funding from the US government’s Operation Warp Speed for the development of the vaccines.
You want to know more about BNT162b2?
This page is based on the article BNT162b2 published in Wikipedia (as of Dec. 10, 2020) and was automatically summarized using artificial intelligence.
